DA Q3W has the potential to provide cost savings over EA QW in terms of annual average drug cost per patient ($654 savings), per member per year ($839 savings), and total cost per population ($1,471,340 savings). DA Q3W may offer a cost advantage over EA QW as it allows for synchronizing of anemia management with ongoing cancer treatments, which may reduce required patient visits and blood tests.
Objectives: To evaluate European physicians' treatment preferences for preventing skeletal-related events (SREs) in patients with bone metastases from solid tumors. MethOds: Physicians completed an online discrete-choice experiment survey consisting of 10 choices between pairs of hypothetical medication profiles for a putative patient. Each profile included five attributes within a pre-defined range (based on prescribing information for the available bone-targeted agents [BTA]): months until first SRE (10, 18 and 28 months); months until worsening of pain (3, 6 and 10 months); annual risk of osteonecrosis of the jaw (ONJ; 0, 1 and 5%); annual risk of renal impairment (0, 4 and 10%); and mode of administration (oral tablet, subcutaneous injection, 15-minute infusion and 120-minute infusion). Choice questions were based on an experimental design with known statistical properties. The survey was pretested with 8 physicians using open-ended interviews. A separate main-effects random parameters logit model was estimated for each country. Results: Physicians from France (n= 191), Germany (n= 192) and the UK (n= 197) completed the survey. Among the attributes included in the survey, months until first SRE and the risk of renal impairement were the most important attributes in France and the UK, whereas in Germany months until first SRE and a delay in worsening of pain were the most important. For all these attributes, better levels were significantly preferred to worse levels (p< 0.05). In all three countries, a 120-minute infusion every 4 weeks was the least preferred mode of administration (p< 0.05). The annual risk of ONJ was judged by physicians to be the least important attribute in all three countries. cOnclusiOns: Physicians generally make treatment decisions regarding choice of BTA for patients with bone metastases based on intent to delay the onset of SREs, managing risk of renal impairment and preventing the worsening of pain.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.